These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24490605)

  • 1. Enobosarm (GTx-024, S-22): a potential treatment for cachexia.
    Srinath R; Dobs A
    Future Oncol; 2014 Feb; 10(2):187-94. PubMed ID: 24490605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
    Dalton JT; Taylor RP; Mohler ML; Steiner MS
    Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
    Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
    Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.
    Zilbermint MF; Dobs AS
    Future Oncol; 2009 Oct; 5(8):1211-20. PubMed ID: 19852734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enobosarm (GTx-024) Modulates Adult Skeletal Muscle Mass Independently of the Androgen Receptor in the Satellite Cell Lineage.
    Dubois V; Simitsidellis I; Laurent MR; Jardi F; Saunders PT; Vanderschueren D; Claessens F
    Endocrinology; 2015 Dec; 156(12):4522-33. PubMed ID: 26393303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
    Dalton JT; Barnette KG; Bohl CE; Hancock ML; Rodriguez D; Dodson ST; Morton RA; Steiner MS
    J Cachexia Sarcopenia Muscle; 2011 Sep; 2(3):153-161. PubMed ID: 22031847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
    Dobs AS; Boccia RV; Croot CC; Gabrail NY; Dalton JT; Hancock ML; Johnston MA; Steiner MS
    Lancet Oncol; 2013 Apr; 14(4):335-45. PubMed ID: 23499390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.
    Anker MS; von Haehling S; Springer J; Banach M; Anker SD
    Int J Cardiol; 2013 Jan; 162(2):73-6. PubMed ID: 23174169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.
    Advani SM; Advani PG; VonVille HM; Jafri SH
    BMC Cancer; 2018 Nov; 18(1):1174. PubMed ID: 30482179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.
    Morimoto M; Aikawa K; Hara T; Yamaoka M
    Oncol Lett; 2017 Dec; 14(6):8066-8071. PubMed ID: 29344250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer cachexia: it's time for more clinical trials.
    Bossola M; Pacelli F; Tortorelli A; Doglietto GB
    Ann Surg Oncol; 2007 Feb; 14(2):276-85. PubMed ID: 17094025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical results in cachexia therapeutics.
    Crawford J
    Curr Opin Clin Nutr Metab Care; 2016 May; 19(3):199-204. PubMed ID: 26974316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of androgens for cachexia.
    Giovanelli L; Quinton R
    Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101598. PubMed ID: 34801415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials.
    Molfino A; Amabile MI; Giorgi A; Monti M; D'Andrea V; Muscaritoli M
    Expert Opin Investig Drugs; 2019 Aug; 28(8):733-740. PubMed ID: 31347405
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.
    Solomon ZJ; Mirabal JR; Mazur DJ; Kohn TP; Lipshultz LI; Pastuszak AW
    Sex Med Rev; 2019 Jan; 7(1):84-94. PubMed ID: 30503797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on promising agents for the treatment of cancer cachexia.
    Madeddu C; Mantovani G
    Curr Opin Support Palliat Care; 2009 Dec; 3(4):258-62. PubMed ID: 19667995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor.
    Liva SG; Tseng YC; Dauki AM; Sovic MG; Vu T; Henderson SE; Kuo YC; Benedict JA; Zhang X; Remaily BC; Kulp SK; Campbell M; Bekaii-Saab T; Phelps MA; Chen CS; Coss CC
    EMBO Mol Med; 2020 Feb; 12(2):e9910. PubMed ID: 31930715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator.
    Weinblatt D; Roy S
    J Med Cases; 2022 May; 13(5):244-248. PubMed ID: 35655632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism and novel therapeutic approaches to wasting in chronic disease.
    Ebner N; Springer J; Kalantar-Zadeh K; Lainscak M; Doehner W; Anker SD; von Haehling S
    Maturitas; 2013 Jul; 75(3):199-206. PubMed ID: 23664695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to the treatment of cachexia.
    Argilés JM; López-Soriano FJ; Busquets S
    Drug Discov Today; 2008 Jan; 13(1-2):73-8. PubMed ID: 18190867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.